Bio-Rad Laboratories Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Bio-Rad Laboratories şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

4.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	4.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BUWA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BUWA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Bio-Rad Laboratories Piyasaya Karşı Temettü Getirisi

BUWA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BUWA)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Life Sciences)	0.7%
Analist tahmini (BUWA) (3 yıla kadar)	0%

Önemli Temettü: BUWA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BUWA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BUWA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BUWA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Bio-Rad Laboratories Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)

Bio-Rad Laboratories, Inc. Announces Executive Changes

Second quarter 2024 earnings released: US$76.26 loss per share (vs US$39.59 loss in 2Q 2023)

Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024

First quarter 2024 earnings released: EPS: US$13.46 (vs US$2.33 in 1Q 2023)

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group

Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024

Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024

Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024

Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer

Full year 2023 earnings released: US$21.82 loss per share (vs US$122 loss in FY 2022)

Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024

Third quarter 2023 earnings released: EPS: US$3.65 (vs US$5.52 loss in 3Q 2022)

Bio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Chief Financial Officer, Effective November 6, 2023

Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023

Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$39.59 loss per share (vs US$31.12 loss in 2Q 2022)

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Senior VP & Chief Accounting Officer recently sold €68k worth of stock

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$2.33 (vs US$113 loss in 1Q 2022)

Executive VP recently sold €344k worth of stock

Full year 2022 earnings released: US$122 loss per share (vs US$142 profit in FY 2021)

Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Senior VP & Chief Accounting Officer recently sold €157k worth of stock

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: US$5.52 loss per share (vs US$132 profit in 3Q 2021)

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Bio-Rad Laboratories, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Senior VP & Chief Accounting Officer recently sold €274k worth of stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Second quarter 2022 earnings released: US$31.12 loss per share (vs US$30.71 profit in 2Q 2021)

Bio-Rad Laboratories, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Now 23% undervalued after recent price drop

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from Russell 1000 Value-Defensive Index

High number of new directors

First quarter 2022 earnings released: US$113 loss per share (vs US$32.77 profit in 1Q 2021)

Insufficient new directors

Bio-Rad Laboratories, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 26, 2022

Bio-Rad Laboratories, Inc. Announces Board Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$132 (vs US$44.24 in 3Q 2020)

Executive VP & CFO recently sold €186k worth of stock

Insider recently sold €404k worth of stock

Executive VP & CFO recently sold €572k worth of stock

Second quarter 2021 earnings released: EPS US$30.71 (vs US$32.59 in 2Q 2020)

Bio-Rad Launches Its Prevalence Ddpcr Sars-Cov-2 Wastewater Quantification Kit for Covid-19 Wastewater Testing

First quarter 2021 earnings released: EPS US$32.75 (vs US$22.97 in 1Q 2020)

Executive VP recently sold €276k worth of stock

Full year 2020 earnings released: EPS US$128 (vs US$58.93 in FY 2019)

Revenue beats expectations

New 90-day high: €535

Bio-Rad Laboratories, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Insider recently sold €179k worth of stock

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

New 90-day high: €490

Bio-Rad Laboratories, Inc. to Report Q3, 2020 Results on Oct 29, 2020

New 90-day high: €466

Bio-Rad Laboratories, Inc. (NYSE:BIO) acquired Celsee, Inc. for approximately $160 million.

Executive VP & Chief Strategy Officer recently sold €1.0m worth of stock

Bio-Rad Laboratories, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from Russell 1000 Dynamic Index